drugset / Trial / NCT04151329

A Phase I Clinical Trial of BAT1306 and BAT8001 Injection in Patients With Solid Tumor

NCT04151329

Phase 1/2 Unknown 72 enrolled Bio-Thera Solutions
SequentialOpen-labelTreatment

Summary

A Phase I Clinical Trial of BAT1306 and BAT8001 Injection in Patients With HER2-positive Advanced Solid Tumor

Timeline

Start
2019-06-21
Primary completion
2020-12-31
Completion
2021-06-30

Drugs

EvaluationDrugModalityDoseRoute
Subject BAT8001 Monoclonal antibody 2.4 mg/kg Intravenous
Subject BAT8001 Monoclonal antibody 3.6 mg/kg Intravenous
Background BAT1306 Unknown 200 mg Intravenous

Indications